A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on June 1, 2025, with the following interim recommendations made:

• Esomeprazole or its salts, for human use, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole, remain in Schedule III.

• Esomeprazole or its salts, for human use, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes containing greater than 280 mg of esomeprazole, be granted Schedule II status.

Any objections to these interim recommendations must be received by the NAPRA office by end of day July 9, 2025. Questions or comments should be directed to the NDSAC Secretariat via email at ndsac@napra.ca.